Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 200mcg/2mL (100mcg/mL) single-dose glass vial
- Requires further dilution before administering
ready-to-use injectable solution
- 80mcg/20mL 0.9% NaCl (4mcg/mL)
- 200mcg/50mL 0.9% NaCl (4mcg/mL)
- 400mcg/100mL 0.9% NaCl (4mcg/mL)
- 1000mcg/250mL 0.9% NaCl (4mcg/mL)
film, sublingual
- 120mg
- 180mg
ICU Sedation
Indicated for sedation of initially intubated and mechanically ventilated patients in ICU setting
Load: 1 mcg/kg IV over 10 minutes; loading dose may not be required for adults converted from other sedative therapy
Maintenance 0.2-0.7 mcg/kg/hr continuous IV infusion; not to exceed 24 hr
Dexmedetomidine has been continuously infused in mechanically ventilated patients before, during, and after extubation; it is not necessary to discontinue dexmedetomidine before extubation
Procedural Sedation
Indicated for sedation of nonintubated patients before and/or during surgical and other procedures
Load: 1 mcg/kg IV over 10 minutes
Maintenance 0.6 mcg/kg/hr IV titrate to effect (usually 0.2-1 mcg/kg/hr)
Awake fiberoptic intubation
Agitation Associated with Schizophrenia or Bipolar Disorder
Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
Assess vital signs including orthostatic measurements before administering
Mild or moderate
- 120 mcg SL or buccal (BUC) initially
- If agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 240 mcg/day
Severe
- 180 mcg SL or BUC initially
- If agitation persists, may give 90 mcg for up to 2 doses at least 2 hr apart; not to exceed 360 mcg/day
Dosage Modifications
IV
- Consider dose reduction in patients with hepatic impairment or aged ≥65 yr; clearance decreases with increasing severity of hepatic impairment
- Renal impairment: No dosage adjustment required
Renal impairment (SL, BUC)
All severities: No dosage adjustment necessary
Hepatic impairment (SL, BUC)
Mild or moderate (Child-Pugh A or B)
- Mild or moderate agitation: 90 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 210 mcg/day
- Severe agitation: 120 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 240 mcg/day
Severe (Child-Pugh C)
- Mild or moderate agitation: 60 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 180 mcg/day
- Severe agitation: 90 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 210 mcg/day
Dosing Considerations
SL/BUC only
- 120-mcg and 180-mcg SL film may be cut in half to obtain 60-mcg and 90-mcg doses
- Due to risk of hypotension, additional half-doses are not recommended in patients with systolic blood pressure (SBP) <90 mmHg, diastolic blood pressure (DBP) <60 mmHg, heart rate (HR) <60 beats per minute, or postural decrease in SBP ≥20 mmHg or in DBP ≥ 10 mmHg
- Limitation of use (Igalmi): Safety and effectiveness not established beyond 24 hr from the first dose
Procedural Sedation
Indicated for sedation of nonintubated children aged ≥1 month before and/or during surgical and other procedures
<1 month: Safety and efficacy not established
Initiation of sedation during noninvasive procedures
- 1 month to <2 years: Loading infusion of 1.5 mcg/kg IV; infuse over 10 minutes
- 2 years to <18 years: Loading infusion of 2 mcg/kg IV; infuse over 10 minutes
- Consider dose reduction if clinically indicated
Maintenance of sedation during noninvasive procedures
- 1 month to <18 years: 1.5 mcg/kg/hr IV initially; titrate to achieve desired clinical effect with dose range of 0.5-1.5 mcg/kg/hr
- As clinically warranted, titrate maintenance dose to individual patient clinical response
Dosage Modifications
Coadministration with anesthetics, sedatives, hypnotics, or opioids
- Consider dose reduction of dexmedetomidine or concomitant anesthetic, sedative, hypnotic, or opioid
- Coadministration is likely to lead to enhanced CNS depressant effects
Hepatic impairment
- Dexmedetomidine clearance decreases with increasing severity of hepatic impairment, consider dose reduction in patients with impaired hepatic function
ICU Sedation
Indicated for sedation of initially intubated and mechanically ventilated patients in ICU setting
Load: 1 mcg/kg IV over 10 minutes; loading dose may not be required for adults converted from other sedative therapy
Maintenance 0.2-0.7 mcg/kg/hr continuous IV infusion; not to exceed 24 hr
Dexmedetomidine has been continuously infused in mechanically ventilated patients before, during, and after extubation; it is not necessary to discontinue dexmedetomidine before extubation
Procedural Sedation
Indicated for sedation of nonintubated patients before and/or during surgical and other procedures
Load: 1 mcg/kg IV over 10 minutes
Maintenance 0.6 mcg/kg/hr IV titrate to effect (usually 0.2-1 mcg/kg/hr)
Awake fiberoptic intubation
Load: 1 mcg/kg IV over 10 minutes
Maintenance 0.7 mcg/kg/hr IV until endotracheal tube secured
Agitation Associated with Schizophrenia or Bipolar Disorder
Indicated in adults for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
Assess vital signs including orthostatic measurements before administering of any subsequent doses
Mild, moderate, or severe
- 120 mcg SL or buccal (BUC) initially
- If agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 240 mcg/day
Dosage Modifications
IV
- Consider dose reduction in patients with hepatic impairment or aged ≥65 yr; clearance decreases with increasing severity of hepatic impairment
- Renal impairment: No dosage adjustment required
Renal impairment (SL/BUC)
- All severities: No dosage adjustment necessary
Hepatic impairment (SL/BUC)
Mild or moderate (Child-Pugh A or B)
- Mild or moderate agitation: 90 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 210 mcg/day
- Severe agitation: 120 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 240 mcg/day
Severe (Child-Pugh C)
- Mild or moderate agitation: 60 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 180 mcg/day
- Severe agitation: 90 mcg SL initially; if agitation persists, may give 60 mcg for up to 2 doses at least 2 hr apart; not to exceed 210 mcg/day
Dosing Considerations
SL/BUC
- 120-mcg and 180-mcg SL tablets may be cut in half to obtain 60-mcg and 90-mcg doses
- Due to risk of hypotension, additional half-doses are not recommended in patients with systolic blood pressure (SBP) <90 mmHg, diastolic blood pressure (DBP) <60 mmHg, heart rate (HR) <60 beats per minute, or postural decrease in SBP ≥20 mmHg or in DBP ≥ 10 mmHg
- Limitation of use (Igalmi): Safety and effectiveness not established beyond 24 hr from the first dose
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (2)
- eliglustat
dexmedetomidine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.
- fezolinetant
dexmedetomidine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitors
Serious - Use Alternative (11)
- calcium/magnesium/potassium/sodium oxybates
dexmedetomidine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- hydrocodone
hydrocodone, dexmedetomidine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- lonafarnib
dexmedetomidine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.
- metoclopramide intranasal
dexmedetomidine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
dexmedetomidine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- ponesimod
ponesimod, dexmedetomidine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.
- ropeginterferon alfa 2b
ropeginterferon alfa 2b and dexmedetomidine both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.
- sodium oxybate
dexmedetomidine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- sufentanil SL
sufentanil SL, dexmedetomidine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- valerian
valerian and dexmedetomidine both increase sedation. Avoid or Use Alternate Drug.
- vortioxetine
dexmedetomidine increases levels of vortioxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Decrease vortioxetine dose by 50% when coadministered with strong CYP2D6 inhibitors.
Monitor Closely (199)
- albuterol
dexmedetomidine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
dexmedetomidine and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
alprazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- amitriptyline
dexmedetomidine and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
amobarbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- amoxapine
dexmedetomidine and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
dexmedetomidine and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
dexmedetomidine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
dexmedetomidine and aripiprazole both increase sedation. Use Caution/Monitor.
- armodafinil
dexmedetomidine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- atogepant
dexmedetomidine will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- avapritinib
dexmedetomidine will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- axitinib
dexmedetomidine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- azelastine
azelastine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- baclofen
dexmedetomidine and baclofen both increase sedation. Use Caution/Monitor.
- belladonna and opium
dexmedetomidine and belladonna and opium both increase sedation. Use Caution/Monitor.
- benazepril
dexmedetomidine, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.
- benperidol
dexmedetomidine and benperidol both increase sedation. Use Caution/Monitor.
- benzphetamine
dexmedetomidine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexpiprazole
dexmedetomidine will increase the level or effect of brexpiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. If also administered with a strong/moderate CYP3A4 inhibitor, administer a quarter of brexpiprazole dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD.
- brompheniramine
brompheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- buprenorphine
dexmedetomidine and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
dexmedetomidine and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine, long-acting injection
dexmedetomidine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.
- butabarbital
butabarbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- butorphanol
dexmedetomidine and butorphanol both increase sedation. Use Caution/Monitor.
- caffeine
dexmedetomidine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- captopril
dexmedetomidine, captopril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.
- carbinoxamine
carbinoxamine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- carisoprodol
dexmedetomidine and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, dexmedetomidine. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and dexmedetomidine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and dexmedetomidine both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- chlorpromazine
dexmedetomidine and chlorpromazine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
dexmedetomidine and chlorzoxazone both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- clemastine
clemastine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- clomipramine
dexmedetomidine and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
clonazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and dexmedetomidine both increase sedation. Use Caution/Monitor.
- clozapine
dexmedetomidine and clozapine both increase sedation. Use Caution/Monitor.
- codeine
dexmedetomidine and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
cyclizine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
dexmedetomidine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dantrolene
dexmedetomidine and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
dexmedetomidine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desflurane
desflurane and dexmedetomidine both increase sedation. Use Caution/Monitor.
- desipramine
dexmedetomidine and desipramine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
dexchlorpheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
dexmedetomidine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmethylphenidate
dexmedetomidine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
dexmedetomidine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
dexmedetomidine and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
dexmedetomidine and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, dexmedetomidine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- dichlorphenamide
dichlorphenamide and dexmedetomidine both decrease serum potassium. Use Caution/Monitor.
- diethylpropion
dexmedetomidine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and dexmedetomidine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
dexmedetomidine and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and dexmedetomidine both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
dexmedetomidine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
dexmedetomidine and dipipanone both increase sedation. Use Caution/Monitor.
- dobutamine
dexmedetomidine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopamine
dexmedetomidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
dexmedetomidine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
dexmedetomidine and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
dexmedetomidine and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
dexmedetomidine and doxylamine both increase sedation. Use Caution/Monitor.
- droperidol
dexmedetomidine and droperidol both increase sedation. Use Caution/Monitor.
- eluxadoline
dexmedetomidine increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors.
- ephedrine
dexmedetomidine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
dexmedetomidine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
dexmedetomidine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- estazolam
estazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- ethanol
dexmedetomidine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and dexmedetomidine both increase sedation. Use Caution/Monitor.
- fenfluramine
dexmedetomidine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- finerenone
dexmedetomidine will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.
- flibanserin
dexmedetomidine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.
dexmedetomidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. - fluphenazine
dexmedetomidine and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
flurazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- formoterol
dexmedetomidine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ganaxolone
dexmedetomidine and ganaxolone both increase sedation. Use Caution/Monitor.
- gotu kola
gotu kola increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- haloperidol
dexmedetomidine and haloperidol both increase sedation. Use Caution/Monitor.
- hawthorn
hawthorn increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hops
hops increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hydromorphone
dexmedetomidine and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- iloperidone
dexmedetomidine and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
dexmedetomidine and imipramine both increase sedation. Use Caution/Monitor.
- isoproterenol
dexmedetomidine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ivacaftor
dexmedetomidine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .
- kava
kava increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- ketamine
ketamine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
dexmedetomidine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lemborexant
dexmedetomidine will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.
- levalbuterol
dexmedetomidine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levorphanol
dexmedetomidine and levorphanol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
dexmedetomidine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
dexmedetomidine and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
dexmedetomidine and lofexidine both increase sedation. Use Caution/Monitor.
- lomitapide
dexmedetomidine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.
- loprazolam
loprazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- lormetazepam
lormetazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- loxapine
dexmedetomidine and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
dexmedetomidine and loxapine inhaled both increase sedation. Use Caution/Monitor.
- lurasidone
lurasidone and dexmedetomidine both increase pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS effects
- maprotiline
dexmedetomidine and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
dexmedetomidine and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
dexmedetomidine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
dexmedetomidine and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
dexmedetomidine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
dexmedetomidine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
dexmedetomidine and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
dexmedetomidine and methadone both increase sedation. Use Caution/Monitor.
- methamphetamine
dexmedetomidine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
dexmedetomidine and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
dexmedetomidine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
midazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- midazolam intranasal
dexmedetomidine will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.
midazolam intranasal, dexmedetomidine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. - midodrine
dexmedetomidine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mirtazapine
dexmedetomidine and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
dexmedetomidine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
dexmedetomidine and morphine both increase sedation. Use Caution/Monitor.
- motherwort
dexmedetomidine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
dexmedetomidine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
dexmedetomidine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
dexmedetomidine and nalbuphine both increase sedation. Use Caution/Monitor.
- norepinephrine
dexmedetomidine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
dexmedetomidine and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
dexmedetomidine and olanzapine both increase sedation. Use Caution/Monitor.
- oliceridine
dexmedetomidine, oliceridine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- opium tincture
dexmedetomidine and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
dexmedetomidine and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
oxazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- oxycodone
dexmedetomidine and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
dexmedetomidine and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
dexmedetomidine and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
dexmedetomidine and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
dexmedetomidine and papaverine both increase sedation. Use Caution/Monitor.
- passion flower
passion flower increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentazocine
dexmedetomidine and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- perphenazine
dexmedetomidine and perphenazine both increase sedation. Use Caution/Monitor.
- phendimetrazine
dexmedetomidine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- phentermine
dexmedetomidine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
dexmedetomidine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
dexmedetomidine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
dexmedetomidine and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
dexmedetomidine and pimozide both increase sedation. Use Caution/Monitor.
- pirbuterol
dexmedetomidine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- primidone
primidone and dexmedetomidine both increase sedation. Use Caution/Monitor.
- prochlorperazine
dexmedetomidine and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
promethazine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- propofol
propofol and dexmedetomidine both increase sedation. Use Caution/Monitor.
- propylhexedrine
dexmedetomidine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
dexmedetomidine and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
quazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- quetiapine
dexmedetomidine and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
dexmedetomidine and ramelteon both increase sedation. Use Caution/Monitor.
- risperidone
dexmedetomidine and risperidone both increase sedation. Use Caution/Monitor.
- salmeterol
dexmedetomidine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scullcap
dexmedetomidine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and dexmedetomidine both increase sedation. Use Caution/Monitor.
- sevoflurane
sevoflurane and dexmedetomidine both increase sedation. Use Caution/Monitor.
- shepherd's purse
dexmedetomidine and shepherd's purse both increase sedation. Use Caution/Monitor.
- sufentanil
dexmedetomidine and sufentanil both increase sedation. Use Caution/Monitor.
- tamoxifen
dexmedetomidine, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. CYP2D6 inhibition decreases metabolism of tamoxifen to hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.
- tamsulosin
dexmedetomidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- tapentadol
dexmedetomidine and tapentadol both increase sedation. Use Caution/Monitor.
- tazemetostat
dexmedetomidine will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- temazepam
temazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- terbutaline
dexmedetomidine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
dexmedetomidine and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
dexmedetomidine and thiothixene both increase sedation. Use Caution/Monitor.
- tinidazole
dexmedetomidine will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- topiramate
dexmedetomidine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
dexmedetomidine and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
dexmedetomidine and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
triazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- triclofos
dexmedetomidine and triclofos both increase sedation. Use Caution/Monitor.
- trifluoperazine
dexmedetomidine and trifluoperazine both increase sedation. Use Caution/Monitor.
- trimipramine
dexmedetomidine and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
triprolidine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- valbenazine
dexmedetomidine will increase the level or effect of valbenazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Consider reducing valbenazine dose based on tolerability if coadministered with a strong CYP2D6 inhibitor.
- valerian
valerian increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- xylometazoline
dexmedetomidine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
dexmedetomidine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
dexmedetomidine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
dexmedetomidine and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
dexmedetomidine and zotepine both increase sedation. Use Caution/Monitor.
Minor (8)
- ashwagandha
ashwagandha increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
- brimonidine
brimonidine increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- eucalyptus
dexmedetomidine and eucalyptus both increase sedation. Minor/Significance Unknown.
- nettle
nettle increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.
- ruxolitinib
dexmedetomidine will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ruxolitinib topical
dexmedetomidine will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- sage
dexmedetomidine and sage both increase sedation. Minor/Significance Unknown.
- Siberian ginseng
Siberian ginseng increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
Adverse Effects
>10%
Hypotension (25-28%)
Hypertension (12-16%)
Nausea (9-11%)
1-10%
Bradycardia (5-7%)
Pyrexia (4-5%)
Atrial fibrillation (4%)
Dry mouth (3-4%)
Vomiting (3-4%)
Hypoxia (2-4%)
Hypovolemia (3%)
Atelectasis (3%)
Tachycardia (2-3%)
Postprocedural hemorrhage (2-3%)
Anemia (2-3%)
Agitation (2%)
Hyperthermia (2%)
Pain (2%)
Hyperglycemia (2%)
Chills or rigors (2%)
Hyperglycemia (2%)
Oliguria (2%)
Thirst (2%)
Acidosis (1-2%)
Pleural effusion (1-2%)
Pulmonary edema (1%)
Hypocalcemia (1%)
Urine output decreased (1%)
Sinus tachycardia (1%)
<1%
Ventricular tachycardia
Wheezing
Peripheral edema
Postmarketing Reports
Blood and lymphatic system disorders: Anemia
Cardiac disorders: Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia
Eye disorders: Photopsia, visual impairment
Gastrointestinal disorders: Abdominal pain, diarrhea, nausea, vomiting
General: Chills, hyperpyrexia, pain, pyrexia, thirst
Investigations: AST/ALT increased, blood alkaline phosphatase increased, blood urea increased, EKG T wave inversion, GGT increased, QT prolonged
Metabolism and nutrition disorders: Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia
Nervous system disorders: Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder
Psychiatric disorders: Agitation, confusional state, delirium, hallucination, illusion
Renal and urinary disorders: Oliguria, polyuria
Respiratory, thoracic, and mediastinal disorders: Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis
Skin and subcutaneous tissue disorders: Hyperhidrosis, pruritus, rash, urticaria
Surgical and medical procedures: Light anesthesia
Vascular disorders: Blood pressure fluctuation, hemorrhage, hypertension, hypotension
Warnings
Contraindications
None
Cautions
Continuously monitor patients while on therapy; IV should only be administered only by persons skilled in managing patients in the intensive care or operating room setting
Bradycardia and sinus arrest have occurred in young healthy volunteers with high vagal tone or with different routes of administration, including rapid IV bolus administration
Caution with advanced heart block and/or severe ventricular dysfunction; because dexmedetomidine decreases sympathetic nervous system activity, hypotension and/or bradycardia may more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in older patients
Transient hypertension reported primarily during loading dose; consider reduction in loading infusion rate
Prolongs QT interval; avoid use in patients at risk of torsades de pointes or sudden death including those with known QT prolongation, a history of other arrhythmias, symptomatic bradycardia, hypokalemia, or hypomagnesemia, and in patients receiving other drugs known to prolong the QT interval
May cause somnolence; advise patients not to perform activities requiring mental alertness (eg, operating a motor vehicle, operating hazardous machinery) for at least 8 hr after administering
Withdrawal symptoms after discontinuation reported when administered for longer than 6 hr; most common events reported include nausea, vomiting, and agitation; in pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation seen after discontinuation of short-term (<2 hours) infusions
Use of another dexmedetomidine product administered IV beyond 24 hr has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions
Not studied for >24 hr after first dose
Drug interaction overview
-
Drugs that prolong the QT Interval
- Avoid coadministration
- Drugs that prolong the QT interval may potentiate to the QT-prolonging effects of dexmedetomidine and increase the risk of cardiac arrhythmia
-
Anesthetics, sedatives, hypnotics, and opioids
- Consider a dose reduction of dexmedetomidine or the concomitant anesthetic, sedative, hypnotic, or opioid
- Coadministration of dexmedetomidine with anesthetics, sedatives, hypnotics, or opioids is likely to lead to enhanced CNS depressant effects
- Specific studies with dexmedetomidine product given IV have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam
Pregnancy & Lactation
Pregnancy
Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage
Reported exposures occurred after the first trimester
Majority of the available data have not identified an adverse effect on maternal outcomes or infant Apgar scores
Available data indicate that dexmedetomidine crosses the placenta
Animal studies
- Fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day
- Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than clinical dose from late pregnancy through lactation and weaning
- In pregnant rats, dexmedetomidine placental transfer observed when radiolabeled dexmedetomidine was administered SC
- Thus, fetal exposure should be expected in humans; use during pregnancy only if potential benefits justify potential fetal risk
Lactation
Presence of dexmedetomidine reported in human milk following IV administration
There is no information regarding effects of dexmedetomidine on breastfed children or the effects on milk production
Advise women to monitor the breastfed infant for irritability
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Centrally acting alpha2-adrenoceptor agonist
Sedation
- Elicits sedative and anesthetic properties by activating G-proteins in the brainstem, which results in inhibition of norepinephrine release
Agitation
- Mechanism of action of acute treatment of agitation associated with schizophrenia or bipolar I or II disorder may be due to activation of presynaptic alpha-2 adrenergic receptors
Absorption
Mean time to dissolve: 6-8 min (SL); 18 min (BUC)
Absolute bioavailability: 72% (SL); 82% (BUC)
Peak plasma time: ~2 hr
Peak plasma concentration
- SL: 143 ng/mL
- BUC: 144 ng/mL
AUC
- SL: 851 ng⋅hr/mL
- BUC: 584 ng⋅hr/mL
Distribution
- Vd (steady-state): 118 L (IV)
- Protein bound: 94% (IV)
Metabolism
Major metabolic pathways of dexmedetomidine are
- Direct N-glucuronidation to inactive metabolites
- Aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19)
-
Aliphatic hydroxylation metabolites
- Generates 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxydexmedetomidine
- N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O-glucuronide
Elimination
Clearance:~39 L/hr (IV)
Half-life
- SL or BUC: ~2.8 hr
- Excretion (IV): Urine (95%); feces (4%)
Administration
IV Incompatibilities
Y-site: amphotericin B, diazepam
IV Compatibilities
Solution: D5W, LR, 0.9% NaCl, mannitol 20%, MgSO4 100 mg/mL, KCl 0.3%
IV Preparation
200 mcg/2 mL (100 mcg/mL) vial
- Dilute with 0.9% NaCl to resulting in a concentration of 4 mcg/mL)
- Preparation of solutions is the same, whether for the loading dose or maintenance infusion
- Withdraw 2 mL of 100 mcg/mL dexmedetomidine and add to 48 mL of 0.9% NaCl to a total of 50 mL
- Shake gently to mix well
Premixed glass containers
- Ready to use
- No further dilution is necessary
IV Administration
Use controlled infusion device; use components made with synthetic or coated natural rubber gaskets
Infuse loading dose over 10 min
Maintenance dose: Administer by IV continuous infusion at recommended rate; individualized and adjust infusion rate to desired clinical response
SL/BUC Preparation
Open seal foil pouch by tearing straight across notch
For 60-mcg or 90-mcg doses, remove film from pouch and cut film in half between dots with clean, dry scissors
Discard unused half film
SL/BUC Administration
Administer sublingually or buccally
Do not chew or swallow film
Sublingual administration
- Place film under tongue and close mouth; film will stick in place
- Do not eat or drink for at least 15 minutes after administration
Buccal administration
- Place film behind lower lip and close mouth; film will stick in place
- Do not eat or drink for at least 1 hr after administration
Administer under supervision of a healthcare provider
Monitor vital signs and alertness after administration to prevent falls and syncope
Storage
IV
- Store at controlled room temperature of 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)
SL film
- Store at controlled room temperature, 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)
- Keep in foil pouch until ready to administer
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| dexmedetomidine intravenous - | 100 mcg/mL vial |  | |
| Precedex intravenous - | 100 mcg/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
dexmedetomidine intravenous
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
